Bile duct cancer combo trial halted early
NCT ID NCT05998447
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug combination (GEN-001 plus pembrolizumab) in 10 adults with advanced bile duct cancer that had stopped responding to standard treatments. The goal was to see if the combination was safe and could shrink tumors. The trial was terminated early, so final results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ajou University Medical Center
Suwon, 16499, South Korea
-
Asan Medical Center
Seoul, Seoul, 05505, South Korea
-
Korea University Guro Hospital
Seoul, Seoul, 08308, South Korea
-
Samsung Medical Center.
Seoul, Seoul, 06351, South Korea
-
Seoul National University Hospital
Seoul, Seoul, 03080, South Korea
-
Severance Hospital
Seoul, Seoul, 03722, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug home in on Hard-to-Treat cancers?
- Can a new immunotherapy combo shrink Hard-to-Treat tumors?
- Can two targeted drugs boost chemo against a rare Bile-Duct cancer?
- New drug cocktail aims to outperform standard immunotherapy in bile duct cancer
- Liver cancer registry aims to uncover new biomarkers from thousands of patients
- Triple-Drug cocktail targets Hard-to-Treat biliary cancers